IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

This study is looking for adults aged 18 or older. You would need to have a confirmed diagnosis of a solid cancer that is advanced (meaning it has spread) or has returned, and it must be a type that hasn't responded to, or can't be treated with, the usual care options available.

To be considered, your overall health should be good enough to take part in the study, and doctors will look at specific blood tests to make sure your kidneys, liver, and other body systems are working well. You must also have measurable cancer, meaning the doctors can clearly see and measure the tumour.

There are also some reasons why you might not be able to join. For example, if you have other active cancers that need treatment, are pregnant or breastfeeding, or have certain severe medical conditions that could make the study unsafe for you. People with active cancer that has spread to the brain would also not be able to participate.

If you decide to take part, you'll be given the study medicine, IMA402. The first part of the study (Phase 1) will be about finding the safest and most effective dose. This might involve starting with a low dose and slowly increasing it, or possibly decreasing it if needed. Once the best dose is found, more people will join in later parts of the study (Phase 2) to see how well it works against different types of cancer.

Throughout the study, you'll have regular hospital visits. These visits will include check-ups, physical examinations, blood tests, and scans (like CT or MRI scans) to monitor your health and see how the cancer is responding to the treatment. You'll also be asked about any side effects you might be experiencing. The exact number and frequency of visits will depend on which stage of the study you are in, but it will involve ongoing monitoring for a period, with follow-up appointments even after you stop taking the study medicine.